Analysis shows relationship between geographic atrophy growth, worsening vision loss
Key takeaways:
- A post hoc analysis found a relationship between geographic atrophy growth and worsening vision loss.
- Fewer patients who received avacincaptad pegol had a loss of 10, 15 or 20 letters from baseline.
A relationship was found between geographic atrophy growth and worsening vision loss in a post hoc analysis of the phase 3 GATHER1 and GATHER2 pivotal clinical trials investigating avacincaptad pegol, according to Iveric Bio.
“This is the first time a relationship between disease progression and worsening visual acuity has been observed in GA, connecting anatomy and function,” Carl Danzig, MD, said in a press release. “These data suggest that in the ACP-treated group, the reduction in growth of GA resulted in an overall lower rate of vision loss.”
Image: Adobe Stock
Danzig presented the findings at the Association for Research in Vision and Ophthalmology meeting in New Orleans.
At 12 months, fewer patients who received avacincaptad pegol (ACP) had a loss of 10, 15 or 20 letters from baseline at two consecutive visits compared with sham, according to the release.
A previously released post hoc analysis found that there was a 56% risk reduction in the rate of persistent vision loss in patients with geographic atrophy (GA) who received ACP 2 mg compared with sham over 12 months of treatment.
Read more about